Armistice Capital’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-4,000,000
| Closed | -$19.6M | – | 187 |
|
|
2021
Q3 | $19.6M | Buy |
4,000,000
+144,000
| +4% | +$699K | 0.33% | 72 |
|
|
2021
Q2 | $20.4M | Hold |
3,856,000
| – | – | 0.36% | 67 |
|
|
2021
Q1 | $18.5M | Buy |
3,856,000
+1,114,000
| +41% | +$5.82M | 0.43% | 59 |
|
|
2020
Q4 | $11.9M | Hold |
2,742,000
| – | – | 0.4% | 63 |
|
|
2020
Q3 | $11.3M | Hold |
2,742,000
| – | – | 0.41% | 59 |
|
|
2020
Q2 | $7.02M | Hold |
2,742,000
| – | – | 0.31% | 67 |
|
|
2020
Q1 | $7.92M | Buy |
2,742,000
+546,000
| +25% | +$2.45M | 0.49% | 59 |
|
|
2019
Q4 | $8.32M | Buy |
2,196,000
+1,660,000
| +310% | +$7.95M | 0.48% | 53 |
|
|
2019
Q3 | $2.74M | Sell |
536,000
-2,164,000
| -80% | -$13.4M | 0.18% | 57 |
|
|
2019
Q2 | $16.7M | Sell |
2,700,000
-44,000
| -2% | -$253K | 1.06% | 31 |
|
|
2019
Q1 | $19.5M | Buy |
2,744,000
+2,086,000
| +317% | +$18.8M | 1.07% | 29 |
|
|
2018
Q4 | $5.62M | Buy |
+658,000
| New | +$8.56M | 0.43% | 47 |
|
|
2017
Q4 | – | Sell |
-750,000
| Closed | -$15.9M | – | 85 |
|
|
2017
Q3 | $15.9M | Sell |
750,000
-408,000
| -35% | -$7.48M | 1.87% | 16 |
|
|
2017
Q2 | $20.3M | Buy |
1,158,000
+294,000
| +34% | +$4.86M | 2.58% | 10 |
|
|
2017
Q1 | $15.1M | Buy |
864,000
+328,000
| +61% | +$5.59M | 3.12% | 9 |
|
|
2016
Q4 | $9.06M | Buy |
+536,000
| New | +$8.29M | 2.14% | 19 |
|
Armistice Capital's ADMS Position: Q4 2021 in Review
Armistice Capital sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 4,000,000 shares — an estimated $19.6M sold.
Armistice Capital first reported a position in ADMS in Q4 2016 and held it in 16 quarters. The position peaked at $20.4M in Q2 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Armistice Capital reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Armistice Capital sold 4,000,000 Adamas Pharmaceuticals shares in Q4 2021, an estimated $19.6M.
- Armistice Capital first reported a position in Adamas Pharmaceuticals in Q4 2016 and held it in 16 quarters.
- Armistice Capital's Adamas Pharmaceuticals position peaked at $20.4M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Armistice Capital's 13F filing for Q4 2021, filed 14 Feb 2022.